Name: 글로벌 시장 동향
SKU: PH466
Availability: InStock

보고서 요약(국문)

시장 개요
글로벌 바이오시밀러 시장은 2022년 301억 달러 규모에 도달했으며, 2030년까지 767억 달러 규모로 성장할 것으로 예상됩니다. 글로벌 바이오시밀러 시장은 2023년부터 2030년까지 연평균 12.8%의 성장률을 보일 것으로 전망됩니다.
바이오시밀러는 동일한 치료 효과를 유지하면서도 보다 저렴한 대안을 제공함으로써 환자들이 생물학적 치료제를 더 쉽게 이용할 수 있도록 해줍니다. 암, 자가면역 질환, 만성 염증성 질환 등 다양한 질병을 가진 환자들을 위한 치료 범위를 확대하고 의료 서비스의 지속가능성을 향상시키는 데 중요한 역할을 할 수 있습니다.
시장 동향
만성 질환의 증가 추세가 예측 기간 동안 글로벌 바이오시밀러 시장 성장을 견인하고 있습니다.

전 세계적으로 암, 자가면역 질환, 당뇨병과 같은 만성 질환의 유병률이 증가하고 있습니다. 바이오시밀러는 특정 질환에 대한 경제적인 치료 대안을 제공함으로써 환자들이 생명을 구할 수 있는 의약품에 더 쉽게 접근할 수 있도록 돕습니다. 만성 질환 발병률 증가가 바이오시밀러에 대한 수요를 촉진하고 있습니다.
2022년 9월 WHO 데이터 보고서에 따르면, 비전염성 질환(NCD)으로 인한 사망의 대부분(연간 1,790만 명)은 심혈관 질환으로 인한 것이며, 그 뒤를 이어 악성 종양(930만 명), 만성 호흡기 질환(410만 명), 당뇨병(당뇨병으로 인한 신장 질환 사망 포함 200만 명) 순입니다.
미국 식품의약국(FDA)의 바이오시밀러 의약품 승인은 글로벌 바이오시밀러 시장에 미래 성장 기회를 제공합니다.
FDA는 바이오시밀러 제품을 승인하고 안전하고 효과적인 바이오시밀러 출시에 필요한 규제 및 과학적 지침을 제공합니다. 바이오시밀러 의약품의 수용은 환자들이 선택할 수 있는 의약품의 폭을 넓히고 치료 비용을 절감함으로써 의료 접근성을 향상시킬 수 있습니다. 예를 들어, 2022년 9월 FDA는 베그젤마(베바시주맙-add)와 스티무펜드(페그필그라스팀-FPGA)를 승인했습니다.
코로나19 영향 분석
코로나19 팬데믹은 바이오시밀러 시장에 상당한 영향을 미쳤습니다. 바이오시밀러는 보다 합리적인 가격의 대안을 제공함으로써 필수 치료에 대한 접근성을 높일 수 있습니다. 이는 특히 공중 보건 비상사태 발생 시 일부 생물학적 제제에 대한 수요가 증가할 수 있으므로 더욱 중요합니다. 전 세계 규제 기관은 팬데믹 기간 동안 추가 업무량을 관리하고 원격 근무 환경에 적응하는 데 어려움을 겪었습니다. 이로 인해 바이오시밀러의 평가 및 승인이 지연되었을 수 있습니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁이 바이오시밀러 시장에 미치는 영향은 복잡하고 다면적입니다. 분쟁 시나리오는 세계의 지정학적 및 경제적 환경에 위험을 초래할 수 있습니다. 투자자들은 위험 감수 성향이 낮아지거나 다른 분야로 관심을 돌릴 수 있으며, 이는 전 세계 바이오시밀러 연구 개발 프로젝트에 대한 투자 및 자금 조달에 영향을 미칠 수 있습니다.
바이오시밀러 임상 시험은 여러 국가와 지역에서 진행됩니다. 러시아나 우크라이나에서 분쟁으로 인해 시험 장소에 대한 접근이 제한되거나 중단될 경우, 시험 완료, 데이터 수집 및 규제 승인 획득이 지연될 수 있습니다.
세그먼트 분석
글로벌 바이오시밀러 시장은 제품, 기술, 응용 분야, 유통 채널 및 지역별로 세분화됩니다.
단일클론 항체 부문은 예측 기간 동안 시장에서 지배적인 위치를 차지할 것으로 예상됩니다.
단일클론 항체 부문은 2022년 바이오시밀러 시장의 약 1/2을 차지하며 가장 높은 시장 점유율을 기록했습니다. 바이오시밀러 분자에는 바이오시밀러 단일클론 항체(mAb)가 포함됩니다. 이러한 크고 복잡한 단백질은 일반적으로 암이나 류마티스 관절염과 같은 질환 치료에 사용됩니다. 또한 면역 체계에서 박테리아, 바이러스 등을 포함한 침입 물질을 인식하고 파괴하는 데 사용됩니다.

예를 들어, 2022년 9월 생명공학 기업인 바이오젠(Biogen Inc.)은 유럽의약품청(EMA)이 항인터루킨-6 수용체 단일클론항체인 로악템라(RoACTEMRA, 토실리주맙)를 참조하는 바이오시밀러 후보물질인 BIIB800의 판매 허가 신청을 승인했다고 발표했습니다.
지역 분석
주요 업체 간의 협력 및 파트너십 증가, FDA 승인 건수 증가, 바이오시밀러 기술의 발전이 북미 지역을 주도하고 있습니다.
북미는 바이오시밀러 시장의 약 32.1%를 차지하며 시장을 주도할 것으로 예상됩니다. 예를 들어, 바이오시밀러에 대한 FDA의 신속한 승인 절차는 환자들이 고품질의 저렴한 의료 서비스를 이용할 수 있도록 지원합니다. 2022년 1월 기준, 미국에서는 33개의 바이오시밀러가 FDA 승인을 받았으며, 그중 21개가 현재 시판 중입니다.

2022년 카디널 헬스 보고서에 따르면, 암 치료 분야에서 리툭시맙, 베바시주맙, 트라스투주맙 등 3가지 계열의 항암제 바이오시밀러가 모두 60% 이상의 시장 점유율을 차지하며 미국에서 바이오시밀러 도입이 크게 진전되었습니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 암젠, 테바, 노바티스, 화이자, 바이오콘, 삼성바이오에피스, 마일란, 셀트리온, 바이오젠, 인타스 등이 있습니다.
보고서 구매 이유

• 제품, 기술, 적용 분야, 유통 채널, 지역별 글로벌 바이오시밀러 시장 세분화를 시각화하고 주요 기업 및 사업자를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 바이오시밀러 시장 수준의 다양한 데이터가 담긴 엑셀 시트를 제공합니다.

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 Excel 파일로 제공됩니다.
글로벌 바이오시밀러 시장 보고서는 약 69개의 표, 70개의 그림, 195페이지 분량입니다.
2023년 주요 독자층
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Biosimilars Market reached US$ 30.1 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 76.7 billion by 2030. The Global Biosimilars Market is expected to exhibit a CAGR of 12.8% during the forecast period 2023-2030.
Biosimilars provide an opportunity to increase patient access to biological therapies by offering more affordable alternatives while maintaining the same therapeutic benefits. They can be essential in enhancing the sustainability of healthcare and broadening the range of available treatments for patients with different illnesses, such as cancer, autoimmune diseases, and chronic inflammatory problems.
Market Dynamics
The growing burden of chronic diseases is boosting the global biosimilars market growth during the forecast period.
Globally, the prevalence of chronic conditions like cancer, autoimmune illnesses, and diabetes is rising. Biosimilars improve patient access to medications that can save their lives by providing economic treatment alternatives for certain ailments. The demand for biosimilars is driven by the rising incidence of chronic diseases.
According to the WHO data report September 2022, the majority of NCD deaths, or 17.9 million people yearly, are caused by cardiovascular illnesses, followed by malignancies (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million including renal disease deaths caused by diabetes).
Approval of biosimilar drugs by the FDA provides the Global Biosimilars Market with future growth opportunities.
The Food and Drug Administration approves biosimilar products and offers the regulatory and scientific guidance required to launch safe and efficient biosimilars. The acceptance of biosimilar pharmaceuticals can increase patient access to care by expanding their selection of medications and possibly lowering their expenses. For instance, in September 2022, FDA approved Vegzelma (bevacizumab-add) and Stimufend (pegfilgrastim-FPGA).
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the biosimilars market. Biosimilars can enhance access to essential treatments by providing more reasonably priced alternatives. This is especially important when there is a public health emergency since the demand for some biologics can go up. Managing the extra workload and adjusting to remote work arrangements during the pandemic has been difficult for regulatory agencies worldwide. The evaluation and approval of biosimilars may have been delayed due to this.
Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on the Biosimilars market is complex and multifaceted. Risks in the geopolitical and economic environment of the world can be caused by conflict scenarios. Investors may become less risk-tolerant or divert their attention to other domains, which could influence investments and funding for biosimilar research and development projects worldwide.
Clinical trials for biosimilars involve several nations and sites. Trial completion, data collection, and gaining regulatory permissions are delayed when the conflict interrupts or restricts access to trial locations in Russia or Ukraine.
Segment Analysis
The global biosimilar market is segmented based on product, technology, application, distribution channel, and region.
The monoclonal antibodies segment is expected to hold a dominant position in the market over the forecast period.
The monoclonal antibodies segment accounted for the highest market stake, accounting for approximately 1/2nd of the Biosimilars market in 2022. The family of biosimilar molecules includes biosimilar monoclonal antibodies (mAbs). Large, complex proteins are typically used to treat conditions like cancer or rheumatoid arthritis. They are employed by the immune system to recognize and destroy invading substances, including bacteria, viruses, and others.
For instance, in September 2022, Biogen Inc., a biotechnology company, declared that the European Medicines Agency had accepted the Marketing Authorization Application for BIIB800, a biosimilar candidate referencing RoACTEMRA (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody.
Geographical Analysis
Increasing collaborations and partnerships among the key players, increasing FDA approvals, and advancement in Biosimilars dominate the North American region.
North America is expected to dominate the Biosimilars market, accounting for around 32.1% of this market. For instance, An expedited FDA approval process for biosimilars is used to increase patient access to high-quality, lower-cost healthcare. In the United States as of January 2022, there were 33 biosimilars that had received FDA approval, 21 of which were currently being sold.
According to the cardinal health report 2022, in cancer, where all three classes of therapeutic oncology biosimilars—namely, rituximab, bevacizumab, and trastuzumab—have topped 60% market share, significant progress has been made in the adoption of biosimilars in the U.S.
Competitive Landscape
The major global players in the market include Amgen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Pfizer Inc., Biocon, Samsung Bioepis, Mylan NV, Celltrion, Biogen, and Intas Pharmaceutical Ltd among others.
Why Purchase the Report?
• To visualize the Global Biosimilar Market segmentation based on the product, technology, application, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Biosimilars market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Biosimilars Market Report Would Provide Approximately 69 Tables, 70 Figures And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Technology
3.3. Snippet by Application
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. An increasing number of biosimilar drug approvals by the FDA is boosting the global biosimilar market growth during the forecast period.
4.1.2. Restraints
4.1.2.1. High development costs of the biosimilar drug are hampering the growth of the global biosimilar market in the forecast period.
4.1.3. Opportunity
4.1.3.1. Technological advancements
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine Conflict Analysis
8. Artificial Intelligence Analysis
9. By Product
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.1.2. Market Attractiveness Index, By Product
9.2. Monoclonal Antibodies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Recombinant Human Growth Hormone (rhGH)
9.4. Insulin
9.5. Anti-coagulants
9.6. Erythropoietin
9.7. Fusion Proteins
9.8. Granulocyte Colony Stimulating Factor
9.9. Follitropin
9.10. Others
10. By Technology
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.1.2. Market Attractiveness Index, By Technology
10.2. Recombinant DNA Technology (rDNA technology)*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Monoclonal Antibodies (MAb) Technology
11. By Application
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.1.2. Market Attractiveness Index, By Application
11.2. Oncology*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Chronic and Immune Diseases
11.4. Infectious Diseases
11.5. Growth Hormone Deficiency
11.6. Blood Disorders
11.7. Others
12. By Distribution Channel
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.1.2. Market Attractiveness Index, By Distribution Channel
12.2. Hospital Pharmacies*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Retail Pharmacies
12.4. Online Pharmacies
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. The U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. The U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. Company Profiles
15.1. Amgen Inc.*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Teva Pharmaceutical Industries Ltd.
15.3. Novartis AG
15.4. Pfizer Inc.
15.5. Biocon
15.6. Samsung Bioepis
15.7. Mylan NV
15.8. Celltrion
15.9. Biogen
15.10. Intas Pharmaceutical Ltd
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us

언급된 주요 기업들

Amgen Inc., 4.	Key Developments, Teva Pharmaceutical Industries Ltd., Novartis AG, Pfizer Inc., Biocon, Samsung Bioepis, Mylan NV, Celltrion, Biogen, Intas Pharmaceutical Ltd

표 목록 (Tables)

List of Tables

Table 1 Global Biosimilars Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Biosimilars Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Biosimilars Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Biosimilars Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Biosimilars Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 6 Global Biosimilars Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 7 Global Biosimilars Market Value, By Application, 2022-2033 (US$ Billion)

Table 8 Global Biosimilars Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 9 Global Biosimilars Market Value, By Region, 2022-2033 (US$ Billion)

Table 10 North America Biosimilars Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 11 North America Biosimilars Market Value, By Application, 2022-2033 (US$ Billion)

Table 12 North America Biosimilars Market Value, By Country, 2022-2033 (US$ Billion)

Table 13 Latin America Biosimilars Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 14 Latin America Biosimilars Market Value, By Application, 2022-2033 (US$ Billion)

Table 15 Latin America Biosimilars Market Value, By Country, 2022-2033 (US$ Billion)

Table 16 Europe Biosimilars Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 17 Europe Biosimilars Market Value, By Application, 2022-2033 (US$ Billion)

Table 18 Europe Biosimilars Market Value, By Country, 2022-2033 (US$ Billion)

Table 19 Asia-Pacific Biosimilars Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 20 Asia-Pacific Biosimilars Market Value, By Application, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Biosimilars Market Value, By Country, 2022-2033 (US$ Billion)

Table 22 Middle East and Africa Biosimilars Market Value, By Product Type, 2022-2033 (US$ Billion)

Table 23 Middle East and Africa Biosimilars Market Value, By Application, 2022-2033 (US$ Billion)

Table 24 Middle East and Africa Biosimilars Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 Amgen Inc.: Overview

Table 26 Amgen Inc.: Product Portfolio

Table 27 Amgen Inc.: Key Developments

Table 28 Pfizer Inc.: Overview

Table 29 Pfizer Inc.: Product Portfolio

Table 30 Pfizer Inc.: Key Developments

Table 31 Sandoz Group AG: Overview

Table 32 Sandoz Group AG: Product Portfolio

Table 33 Sandoz Group AG: Key Developments

Table 34 Teva Pharmaceuticals USA, Inc.: Overview

Table 35 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 36 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 37 Biogen: Overview

Table 38 Biogen: Product Portfolio

Table 39 Biogen: Key Developments

Table 40 Biocon Biologics Inc.: Overview

Table 41 Biocon Biologics Inc.: Product Portfolio

Table 42 Biocon Biologics Inc.: Key Developments

Table 43 Boehringer Ingelheim International GmbH: Overview

Table 44 Boehringer Ingelheim International GmbH: Product Portfolio

Table 45 Boehringer Ingelheim International GmbH: Key Developments

Table 46 Samsung Bioepis: Overview

Table 47 Samsung Bioepis: Product Portfolio

Table 48 Samsung Bioepis: Key Developments

Table 49 Dr. Reddy’s Laboratories Ltd.: Overview

Table 50 Dr. Reddy’s Laboratories Ltd.: Product Portfolio

Table 51 Dr. Reddy’s Laboratories Ltd.: Key Developments

Table 52 Fresenius Kabi AG: Overview

Table 53 Fresenius Kabi AG: Product Portfolio

Table 54 Fresenius Kabi AG: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Biosimilars Market Share, By Product Type, 2024 & 2033 (%)

Figure 3 Global Biosimilars Market Share, By Application, 2024 & 2033 (%)

Figure 4 Global Biosimilars Market Share, By Region, 2024 & 2033 (%)

Figure 5 Global Biosimilars Market Y-o-Y Growth, By Product Type, 2023-2033 (%)

Figure 6 Monoclonal Antibodies Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 7 Recombinant Human Growth Hormone (rhGH) Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 8 Insulin Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 9 Anti-coagulants Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 10 Erythropoietin Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 11 Granulocyte Colony Stimulating Factor Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 12 Follitropin Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 13 Interferons Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 14 Others Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 15 Global Biosimilars Market Y-o-Y Growth, By Application, 2023-2033 (%)

Figure 16 Oncology Application in Global Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 17 Chronic Diseases Application in Global Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 18 Autoimmune Diseases Application in Global Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 19 Infectious Diseases Application in Global Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 20 Growth Hormone Deficiency Application in Global Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 21 Hematology Application in Global Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 22 Others Application in Global Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 23 Global Biosimilars Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 24 North America Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 25 North America Biosimilars Market Share, By Product Type, 2024 & 2033 (%)

Figure 26 North America Biosimilars Market Share, By Application, 2024 & 2033 (%)

Figure 27 North America Biosimilars Market Share, By Country, 2024 & 2033 (%)

Figure 28 Latin America Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 29 Latin America Biosimilars Market Share, By Product Type, 2024 & 2033 (%)

Figure 30 Latin America Biosimilars Market Share, By Application, 2024 & 2033 (%)

Figure 31 Latin America Biosimilars Market Share, By Country, 2024 & 2033 (%)

Figure 32 Europe Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 33 Europe Biosimilars Market Share, By Product Type, 2024 & 2033 (%)

Figure 34 Europe Biosimilars Market Share, By Application, 2024 & 2033 (%)

Figure 35 Europe Biosimilars Market Share, By Country, 2024 & 2033 (%)

Figure 36 Asia-Pacific Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 37 Asia-Pacific Biosimilars Market Share, By Product Type, 2024 & 2033 (%)

Figure 38 Asia-Pacific Biosimilars Market Share, By Application, 2024 & 2033 (%)

Figure 39 Asia-Pacific Biosimilars Market Share, By Country, 2024 & 2033 (%)

Figure 40 Middle East and Africa Biosimilars Market Value, 2022-2033 (US$ Billion)

Figure 41 Middle East and Africa Biosimilars Market Share, By Product Type, 2024 & 2033 (%)

Figure 42 Middle East and Africa Biosimilars Market Share, By Application, 2024 & 2033 (%)

Figure 43 Amgen Inc.: Financials

Figure 44 Pfizer Inc.: Financials

Figure 45 Sandoz Group AG: Financials

Figure 46 Teva Pharmaceuticals USA, Inc.: Financials

Figure 47 Biogen: Financials

Figure 48 Biocon Biologics Inc.: Financials

Figure 49 Boehringer Ingelheim International GmbH: Financials

Figure 50 Samsung Bioepis: Financials

Figure 51 Dr. Reddy’s Laboratories Ltd.: Financials

Figure 52 Fresenius Kabi AG: Financials

글로벌 바이오시밀러 시장 – 2023-2030

Global Biosimilars Market - 2023-2030